COVID-19 Boost As Pharma ROI Hits Heights Not Seen For Seven Years, Finds Deloitte
Expected return on investment for pharma firms jumped sharply to 7% in 2021, driven largely by COVID-19 R&D but even when the pandemic's impact was stripped out, there was an increase in core R&D productivity compared with 2020, a new report from Deloitte has found. The average cost of developing a drug also declined from 2020 to 2021.
You may also be interested in...
The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.